The study will use Biocept’s proprietary CEE (Cell Enrichment and Extraction) technology, designed to capture rare cells from a larger heterogeneous cell population. The focus of this study is ovarian cancer.
The study has three goals- to optimize detection and isolation of circulating tumor cells (CTCs) in ovarian cancer patients, to quantify the levels of CTCs in patients with primary or recurrent ovarian cancer, and to compare gene profiles between CTCs and primary tumor specimens.
Gordon Janko, president and CEO of Biocept, said: “We hope that our ability to isolate and quantify circulating tumor cells will improve cancer detection and treatment by giving physicians valuable information early in the disease course.”